DEVELOPMENT OF VESIVAX CO-ADJUVANT FORMULATION OF 2E151 for flu vaccines

NIH RePORTER · NIH · N43 · $599,925 · view on reporter.nih.gov ↗

Abstract

The contractor will generate analogues of signal modifiers and co-formulate them with monophosphoryl lipid A using the contractor’s proprietary VesiVax liposomal system.

Key facts

NIH application ID
10933265
Project number
75N93023C00033-0-9999-1
Recipient
MOLECULAR EXPRESS, INC.
Principal Investigator
SAM ONHO
Activity code
N43
Funding institute
NIH
Fiscal year
2023
Award amount
$599,925
Award type
—
Project period
2023-09-30 → 2025-09-29